发明名称 |
Methods for treating conditions associated with MASP-2 dependent complement activation |
摘要 |
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. |
申请公布号 |
US8951522(B2) |
申请公布日期 |
2015.02.10 |
申请号 |
US201213441827 |
申请日期 |
2012.04.06 |
申请人 |
University of Leicester;Omeros Corporation |
发明人 |
Demopulos Gregory A.;Dudler Thomas;Schwaeble Hans-Wilhelm |
分类号 |
A61K39/395;C07K16/40;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
Quinton Tineka J.;Kelbon Marcia S. |
主权项 |
1. A method of inhibiting MASP-2-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising administering to the subject a composition comprising an amount of a monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and selectively inhibits MASP-2-dependent complement activation without substantially inhibiting the C1q-dependent complement pathway. |
地址 |
Leicester GB |